Cord Blood America, Inc. (OTC:CBAI.ob), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today that it has purchased a minority interest in Stem Cells VIDAPLUS, a Spanish-owned company which preserves umbilical cord stem cells at the Institute of Transfusion Medicine and Immunology of the Red Cross in Frankfurt, Germany.

“Headquartered in Madrid and founded in 2007, VIDAPLUS (www.vidapluscm.com) is one of the premier stem cell storage companies in Europe.  The Spanish economy is rebounding and we believe this investment both gives Cord Blood America an increased presence in Europe and diversifies our revenue stream,” said Matthew Schissler, Cord Blood America CEO and co-founder.

“The investment is organized in tranches that allows Cord Blood America to increase its stake in the Company over time including, eventually, taking a controlling interest,” Mr. Schissler said.  Cord Blood America previously announced it acquired 51 percent of stellacure GmbH in Germany, which also operates in conjunction with the German Red Cross.

Cord Blood America, Inc. (OTC:CBAI.ob), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced yesterday that Matthew Schissler, CEO and co-founder, explains in detail the plans for the Company’s recapitalization in a ten-minute interview. The video and text of the speech is given below.

According to pharmaceutical research firm IMS Health, U.S. sales of oncology drugs increased only 3.5 percent in the first nine months of 2010, compared to sales growth of 23 percent in 2006, 14 percent in 2007, and 9 percent in 2008 and 2009. The slowdown in sales growth is primarily being caused by price increases as well as the entry of new generics as older, established drugs lose patent protection. The article also noted that many recent drugs are simply variations of existing drugs that wind up jostling for space in an already crowded market.

The article notes that the oncology field will largely be driven by innovation. Those seeking the cancer innovators of tomorrow might take a look at the following companies:

ImmunoCellular Therapeutics‘ (IMUC.OB) cancer vaccine has drawn comparisons to Dendreon’s (DNDN) Provenge. ImmunoCellular is currently advancing a dendritic cell-based vaccine to treat glioblastoma multiforme, the most common form of brain cancer.

Antigenics’ (AGEN) lead product, Oncophage, is a therapeutic cancer vaccine that is formulated to target only cancerous cells. The company is currently recruiting patients for Phase I and II studies of its cancer vaccine for brain and central nervous system tumors. Antigenics was recently awarded $424,720 in grants under the IRS’ Qualifying Therapeutic Discovery Project (QTDP) program for promising therapeutic candidates.

Although Mannkind Corp.’s (MNKD) insulin inhaler (currently in clinical development) has gained the most media attention, the company is also developing a therapeutic cancer vaccine. Last month, the company initiated a Phase II study of its immunotherapy vaccine in patients with advanced melanoma.

Both Curis (CRIS) and Ariad Pharmaceuticals (ARIA) are developing cancer treatments which utilize cell signaling pathways that are linked to cancer.

Coronado Biosciences and Cleveland BioLabs (CBLI) are both developing drugs that target the process of apoptosis, or programmed cell death. Cleveland BioLabs recently dosed the first patient in a multicenter Phase Ib trial of curaxin in patients with liver tumors. The company was also awarded a $244,479 grant under the QTDP program.

Nanospectra Biosciences’ technology turns light into heat for the focused, thermal destruction of solid tumors. On the opposite end of the temperature scale, NuVue Therapeutics utilizes cryotherapy for the site-specific targeting of soft tissue tumors.

OxiGene (OXGN) is targeting ovarian cancer using a new type of therapy known as “vascular disrupting agents,” which works by collapsing the blood vessels inside of the tumor and “starving” it from within.

Threshold Pharmaceuticals (THLD) is developing a tumor-targeting therapy for pancreatic cancer and other solid tumors. The company’s therapeutic platform is based on the concept of “tumor hypoxia,” or low oxygen concentration in the tumor. Threshold’s lead drug candidate, TH-302, is formulated to be activated within hypoxic cells, killing them and those nearby. The drug has demonstrated significant anti-tumor activity in preclinical studies.

LAS VEGAS, Nov. 8, 2010  — Cord Blood America, Inc. (http://www.cordblood-america.com) (OTC:CBAI.ob), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, is pleased to announce that it is the first cord blood stem cell storage company to become an alliance partner of AHIP (America’s Health Insurance Plans), a national association representing nearly 1,300 member companies providing health insurance coverage to more than 200 million Americans.

AHIP members offer medical insurance, long-term care insurance, disability income insurance, supplemental insurance, stop-loss insurance and reinsurance to consumers, employers and public purchasers.  AHIP also provides a unified voice for the community of health insurance plans, with the policy goal of providing high quality, affordable coverage to all Americans.

“This is an excellent opportunity for Cord Blood America to let these premier insurance providers know about the importance of storing umbilical cord blood at birth and the value of insuring the procedure,” said Matthew Schissler, Cord Blood America co-founder, CEO and President.  “We intend to take advantage of our ability to provide these companies a case study on the value of stem cell storage and to attend conferences where we can meet insurance executives face-to-face.”

“We view this as another example of Cord Blood America being ahead of the field, in front of our competitors, with a business strategy that focuses on letting the gatekeepers in the industry know about the value of the service we provide,” Mr. Schissler said.

Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders.

Shares of Cord blood America is severly beaten down after peeking  during the opening of the storage facility in Jan 2010. It is traded at an average price of 0.0039 cents per shares today on Nov 8, 2010.

1.) As of today, there are now 158.1M + 35.7M = 193.8M shares outstanding, with today adding 22.6% more dilution … its now basically doubled over the course of the past year!!!

2.) The Liquid Surfaxin is the Lead Program, and it is targeted to a $75M/yr U.S.-only market opportunity, which is currently served by legacy animal-derived products.

3.) If DSCO captured the entire market, and w/ NO further dilution, then the market cap would be $450M, and the corresponding PPS would be $2.32/share.

4.) The next PDUFA date, for the Liquid Surfaxin, is probably Aug or Sept of next year, 2011, so expect the # of shares outstanding to double again, to ~388M … that would correlate to a best-case PPS upon Approval of ~$1.16/share, but of course that assumes DSCO captures 100% of the market, which it won’t.

5.) Amick panicked when he decided to pursue the latest Offering … why did he do that ??? … if you can figure that out, then you’ll probably have the keys to un-raveling the entire DSCO puzzle.

6.) The Perpetual Silence that occurred between the early-Dec. 2009 ASM and now, will most-likely continue thru the end of this year, till this year’s ASM (again, most-likely in Dec.).

7.) Be prepared for little to no real movement in the stock … it will continue to be controlled by one or more MMs.

8.) DSCO Top Mgmt doesn’t care at all about shareholder value, and if you don’t believe me, I suggest you track the dilution since Amick has been with the company … when he took over as Chairman, the number of shares outstanding was only 70.5M, and the dilution has accelerated since he took over as interim-CEO on Aug. 13th.

Disclosure: Used to be a Long-Term Long, until mid-Oct 2009, when the company rejected numerous outright Buyout offers, and decided to pursue 200M new authorized shares instead … bought my first shares shortly after the early-May 2008 Approvable … I would have lost big time, if it wasn’t for the 9/30 pre-market PR … as it stands, I have ZERO shares now, and an overall loss of $3,214 … but more than that, I wasted ALOT of time trying to understand their drug candidates and market potential, all now moot … I will buy back in, if the PPS trends below $0.20/share, but NOT before … the trade isn’t worth the risk, IMO … and, even then, I may decide NOT to jump back in … I am NOT a fan of either Amick or Cooper, and that is a huge under-statement!

Below are the best-performing U.S. stocks year-to-date.

Ranking  |  Company (Ticker)  |  Year-to-Date Performance

1. Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX) 717.6%
2. Sterling Banks, Inc. (NASDAQ:STBK) 427.9%
3. Zanett, Inc. (NASDAQ:ZANE) 422.6%
4. Graham Packaging Company Inc (NYSE:GRM) 371.2%
5. Star Scientific, Inc. (NASDAQ:CIGX) 298.6%
6. Wabash National Corporation (NYSE:WNC) 282.5%
7. Callon Petroleum Company (NYSE:CPE) 271.3%
8. Semitool, Inc. (NASDAQ:SMTL) 260.3%
9. Aspect Medical Systems, Inc. (NASDAQ:ASPM) 259.8%
10. InterMune, Inc. (NASDAQ:ITMN) 252.8%
11. Adeona Pharmaceuticals, Inc. (AMEX:AEN) 239.3%
12. SMTC Corporation (USA) (NASDAQ:SMTX) 223.9%
13. Bakers Footwear Group, Inc. (NASDAQ:BKRS) 214.7%
14. Ruth’s Hospitality Group, Inc. (NASDAQ:RUTH) 211.9%
15. Houston American Energy Corporation (NASDAQ:HUSA) 201.1%
16. Wave Systems Corp. (NASDAQ:WAVX) 187.3%
17. Servidyne, Inc. (NASDAQ:SERV) 159.9%
18. Tuesday Morning Corporation (NASDAQ:TUES) 149.2%
19. Strategic Hotels & Resorts Inc. (NYSE:BEE) 140.3%
20. Quiksilver, Inc. (NYSE:ZQK) 140.1%
21. CardioDynamics Int’l Corp (NASDAQ:CDIC) 137.2%
22. Rexahn Pharmaceuticals, Inc. (AMEX:RNN) 136.8%
23. Bank of Granite Corporation (NASDAQ:GRAN) 135.3%
24. GenVec, Inc. (NASDAQ:GNVC) 134.2%
25. Green Bankshares, Inc. (NASDAQ:GRNB) 132.4%
26. Presstek, Inc. (NASDAQ:PRST) 132.4%
27. Arrhythmia Research Technology, Inc. (AMEX:HRT) 131.3%
28. Cortex Pharmaceuticals (AMEX:CORX) 130.8%
29. SinoCoking Coal and Coke Chem Ind, Inc. (NASDAQ:SCOK) 129.4%
30. Samson Oil & Gas Limited (ADR) (AMEX:SSN) 129.2%
31. Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) 128.9%
32. Commonwealth Bankshares, Inc. (NASDAQ:CWBS) 128.1%
33. Southern Connecticut Bancorp Inc. (AMEX:SSE) 127.2%
34. Dearborn Bancorp, Inc. (NASDAQ:DEAR) 125.8%
35. Cost Plus, Inc. (NASDAQ:CPWM) 125.5%
36. Maguire Properties, Inc. (NYSE:MPG) 123.2%
37. OccuLogix, Inc. (USA) (NASDAQ:TEAR) 115.2%
38. Morton’s Restaurant Group, Inc. (NYSE:MRT) 113.4%

Let’s look into brief profile of CYCC.  Cyclacel Pharmaceuticals, Inc has various drugs under develipment:  they are:

• Sapacitabine (CYC682):  An oral nucleoside analogue, which is in phase II studies for the treatment of hematological malignancies, , such as acute myeloid leukemia in the elderly, myelodysplastic syndromes, cutaneous T-cell lymphoma, and lung cancer.
• Seliciclib (CYC202): A CDK (cyclin dependent kinase) inhibitor, which is in phase II studies for the treatment of lung cancer and nasopharyngeal cancer.
• CYC116, an Aurora kinase and VEGFR2 inhibitor that is in phase I studies for patients with solid tumors.

The company, through its subsidiary, ALIGN Pharmaceuticals, LLC, markets directly Xclair Cream for radiation dermatitis, as well as Numoisyn Liquid and Numoisyn Lozenges for xerostomia in the United States. It focuses on building a diversified biopharmaceutical business focused in hematology, oncology, and other therapeutic areas based on a portfolio of commercial products and a development pipeline of novel drug candidates.

Now some good points: Cyclacel ended 2009 with cash and cash equivalents of $11.5 million. The company expects its cash balance coupled with the proceeds from recent financings to be sufficient to meet its anticipated short-term working capital needs. Furthermore, they should be able to fund current operations for at least the next twelve months.  So no more dilution for a year at least.

On Januvary 22 nd Cord Blood America started another chapter by opening a Office and Lab atLas Vegas. Here is the video of the event.

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders.

Cord Blood America, today said that it has retired almost $6 million worth of notes which had been provided by Enable Capital Management, LLC and their affiliates between 2007 and 2009.

BEIJING, Nov. 17 /PRNewswire-Asia/ — Sinovac Biotech Ltd. (Nasdaq: SVA – News), a leading developer and provider of vaccines in China, announced today that it received a revised production license from State Food and Drug Administration for Panflu.1, the Company’s H1N1 vaccine. The population has been expanded to include people over 60 years old. The shelf life for PANFLU.1 was extended to one year from six months.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, stated, “The revised license enables Sinovac to provide our H1N1 vaccine to a broader population across China and lengthens the product shelf life. We continue to work closely with Chinese government to provide citizens with international-quality vaccines and to fulfill our mission of supplying vaccines to eliminate human diseases.”

Also Sinovac was selected by the Shanghai Government to supply its inactivated hepatitis A vaccine, Healive®, to the public market of Shanghai. Out of the five vaccine manufacturers that participated in the bidding process, the Shanghai Government awarded Sinovac the entire hepatitis A vaccine purchase order, valued at RMB 20.6 million, or approximately $3 million. Pursuant to the agreement, Sinovac will supply Healive® over the next twelve months.

The purchase plan from the Shanghai Government reflects the continued expansion of government purchase programs for vaccines. This is part of the national expanded immunization program (EPI) funded by the Chinese government.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, remarked, “We are pleased that the Shanghai Government selected Sinovac as the sole manufacturer for this $3 million hepatitis A tender offer. Earlier this year, we established growth for Healive in both the public and private pay markets as a strategic goal. At that time, our newly completed filling and packaging plant had made us well positioned to fulfill existing orders, increase our production scale for meeting the demand from both public market and private market and develop new vaccines. We have done just that, securing large Healive purchase orders from the Shanghai government and China’s Ministry of Public Health, even as we quickly adapted to develop and commercialize PANFLU.1, a time sensitive H1N1 vaccine. The selection confirms our ability to supply our high quality vaccines pursuant to the Government purchasing programs.”

• BioElectronics, the makers of inexpensive Drug Free, Anti-inflammatory Medical Devices and Patches.
• Recently chosen as “One of 9 Medical Breakthroughs That May Change Your Life.”
• Approved for sale in over 20 Countries including Canada, Italy, India and Korea.
• Producers of two product lines, Actipatch for retail sales and RecoveryRx for medical sales.

The study tested the effectiveness of ActiPatch® Therapy versus acetaminophen in reducing the pain of Delayed Onset Muscle Soreness, a condition associated with increased physical exertion.

“We now have an additional Institutional Review Board (IRB) supervised and National Institutes of Health (NIH) registered clinical study that demonstrates what our customers have been saying for years,” said Andrew Whelan, CEO, BioElectronics Corp. “Our products give fast, localized relief from pain and swelling without the danger of drug side effects. We plan to use this additional study to further support our pending 510(K) applications on file at FDA as well as possibly using them in additional applications.”

“In the study more than 100 healthy male and female college athletes and trainers were given a vigorous resistance exercise regimen to induce DOMS. They were then randomly divided into three groups; a group that used ActiPatch for two days, a control group that received no treatment, and a third group that was to be treated with acetaminophen,” commented Sheena Kong, M.D. the principal investigator. “All participants returned approximately 48 hours after the exercise regime. Upon return those in the ActiPatch and control groups immediately rated their levels of muscle pain and soreness using the Visual Analogue Scale. Participants in the acetaminophen group were given one gram of acetaminophen in the form of Extra Strength Tylenol® and then 90 minutes later rated their levels of muscle pain and soreness using the same scale.”

Dr. Kong continued, “The study was conclusive showing that the ActiPatch treated volunteers had significantly less pain than those in either the acetaminophen or control groups. Also of note was the fact that some of the participants assigned to the acetaminophen group were eliminated from the results because they expressed reservations about consuming the drug.”

The report notes that there was a highly significant difference between the control group and the group using the ActiPatch, with the control group indicating an average VAS pain level of 3.179 compared to 1.500 for the ActiPatch group where lower numbers indicate lower pain levels. This difference between the two groups was found to be significant at the .001 level. The difference between the acetaminophen group and the ActiPatch group was also highly significant with the acetaminophen group indicating an average pain level of 2.507, i.e., over one point higher than the ActiPatch group. This difference was found to be significant at the .05 level.

ActiPatch technology truncates the human body’s natural inflammatory response by breaking the cycle of chronic inflammation. ActiPatch does this by delivering sensation-free pulsed electromagnetic energy and RF waves directly to the affected area and driving out the edematous fluid along with byproducts of the damaged tissue. The effect is well documented and results in a significant overall improvement in the restorative and recovery process following a soft tissue injury. This speedier healing results in a significant reduction in the pain associated with the injury. ActiPatch has been used by thousands of people throughout the world and maintains a 100% safety profile.

The study is Institutional Review Board (IRB) supervised and has been registered with the National Institutes of Health. The principal investigator, Sheena Kong, M.D. holds no financial position in any form in the study’s sponsor, BioElectronics Corp., and has not and will not receive financial compensation of any kind for the administration or completion of the study. The acetaminophen used in the study was Extra Strength Tylenol® in 1 gram doses.

A complete copy of the study results and protocol is available on the BioElectronics Corp. web site:http://www.bioelectronicscorp.com.